The Pharmacokinetics of 2% TD1414 Cream in Adults With Secondarily Infected Traumatic Lesions (SITL) or Impetigo
Status:
Completed
Trial end date:
2009-02-01
Target enrollment:
Participant gender:
Summary
A national, prospective single arm phase II study investigating the pharmacokinetics and
safety of the 2% TD1414 cream when applied 3 times daily for 7 days to adult patients with
impetigo or Secondarily Infected Traumatic Lesions (SITL). A total of 20 patients will be
enrolled.